Q32 Bio Reports Positive 36-Week Data for Alopecia Areata Drug Candidate
Q32 Bio Inc. has announced positive 36-week topline results from Part B of its SIGNAL-AA clinical trial for bempikibart in alopecia areata. The drug candidate demonstrated clinically meaningful efficacy and a generally well-tolerated safety profile.
Q32 Bio Inc., a clinical-stage biotechnology company, announced on July 13, 2026, positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata (AA).
The trial's Part B observed clinically meaningful efficacy in the primary endpoint, with a mean percent reduction in the Severity of Alopecia Tool (SALT) score of 35.3% in the modified intent-to-treat (mITT) analysis. Additionally, 40% of patients achieved a SALT-20 response (indicating significant hair regrowth) by week 36 in the mITT analysis.
Bempikibart, a fully human antibody, is designed to re-regulate adaptive immune function by blocking specific signaling pathways. The investigational drug exhibited a generally well-tolerated safety profile consistent with prior studies, with no new safety signals identified. Q32 Bio intends to advance a registration-directed program in the first half of 2027.
Q32 Bio will host a conference call and webcast today, featuring alopecia areata key opinion leader Arash Mostaghimi. These latest results support the further development of bempikibart for alopecia areata, and the company believes the drug holds potential for a broader range of autoimmune and inflammatory diseases.